Publicacións en colaboración con investigadores/as de Hospital Carlos III (125)

2020

  1. Evaluation of the Integrated Tuberculosis Research Program Sponsored by the Spanish Society of Pulmonology and Thoracic Surgery: 11 Years on

    Archivos de Bronconeumologia, Vol. 56, Núm. 8, pp. 483-492

2017

  1. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study

    HIV Medicine, Vol. 18, Núm. 7, pp. 482-489

2016

  1. Spanish Compliance With Guidelines for Prescribing Four Drugs in the Intensive Phase of Standard Tuberculosis Treatment

    Archivos de Bronconeumologia, Vol. 52, Núm. 5, pp. 262-268

2015

  1. Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: The optim study

    PLoS ONE, Vol. 10, Núm. 3

  2. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  3. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

  2. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194

  3. Molecular epidemiology and clinical features of human T cell lymphotropic virus type 1 infection in Spain

    AIDS Research and Human Retroviruses, Vol. 30, Núm. 9, pp. 856-862

  4. Very late HCV relapse following triple therapy for hepatitis C

    Antiviral Therapy

  5. X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain

    AIDS, Vol. 28, Núm. 11, pp. 1603-1609

2013

  1. Hepatitis B in HIV-infected patients

    Clinics in Liver Disease, Vol. 17, Núm. 3, pp. 489-501

  2. Hepatitis B, C, and D and HIV infections among immigrants from equatorial guinea living in Spain

    American Journal of Tropical Medicine and Hygiene, Vol. 88, Núm. 4, pp. 789-794

  3. Hepatitis C therapy with HCV NS5B polymerase inhibitors

    Expert Opinion on Pharmacotherapy, Vol. 14, Núm. 9, pp. 1161-1170

  4. Hepatitis C therapy: Highlights from the 2012 annual meeting of the european association for the study of the liver

    Clinical Infectious Diseases, Vol. 56, Núm. 4, pp. 560-566

  5. Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves

    Journal of Medical Virology, Vol. 85, Núm. 10, pp. 1734-1740

  6. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B

    AIDS, Vol. 27, Núm. 14, pp. 2219-2224

  7. Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy

    Journal of Clinical Virology, Vol. 58, Núm. 2, pp. 391-395

  8. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 9, pp. 1994-2002

  9. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85